- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01517230
Can Mass Media Campaigns Reduce Child Mortality
A cluster-randomised trial will be undertaken in Burkina Faso to investigate whether a comprehensive mass media campaign using local radio stations can change behaviours on a scale large enough to result in measurable and sustainable reductions in under-five child mortality.
It is hypothesised that as a result of the scale and multi-pronged nature of the campaign, reductions of between 10% and 20% in child mortality will be achieved.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The evaluation is conducted in 14 geographical locations throughout Burkina Faso. Seven of these 14 clusters have been randomly allocated to receive the mass media intervention while the remaining 7 clusters will serve as controls.
Data collection includes household surveys in all 14 clusters at three "key" times:
- At baseline: Before the implementation of the intervention, between December 2011 and February 2012 to measure the current level of child mortality and evaluate current knowledge and behaviours of relevance to child health.
- At midline: Fifteen months after implementation of the intervention to evaluate the coverage of the intervention (in the intervention clusters) and, in each cluster, knowledge and behaviours.
- At endline: Two and a half years after implementation of the intervention to evaluate intervention coverage (in the intervention clusters), knowledge and behaviours and child mortality.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bobo-Dioulasso, Burkina Faso, BP 390
- Centre Muraz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Residence in study clusters
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: intervention
seven clusters where radio media campaign will be broadcast.
|
The media campaign is designed by Development Media International.
It includes short "spots" and long format programs broadcast by rural community radios.
Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition.
The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years.
|
No Intervention: control
Seven clusters where radio media campaign won't be broadcast.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Post neonatal under-five all cause mortality
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Under-5 child all cause mortality
Time Frame: 1year
|
1year
|
|
Preventive behaviours for main causes of under-five children mortality
Time Frame: 1 year
|
|
1 year
|
Knowledge
Time Frame: 30-36 months after the start of the intervention
|
|
30-36 months after the start of the intervention
|
Cost-effectiveness of mass media campaigns in terms of dollars per disability-adjusted life year (DALY) averted
Time Frame: 1 year
|
1 year
|
|
Curative behaviours for main causes of under-five children mortality
Time Frame: 15 days
|
Health care behaviours to treat cases of diarrhoea, fever, cough and respiratory difficulties in the youngest under-five child during the 15 previous days
|
15 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Simon N Cousens, MA, London School of Hygiene and Tropical Medicine
- Principal Investigator: Nicolas Meda, MD, PhD, Centre Muraz
- Study Director: Sophie Sarrassat, PhD, London School of Hygienne and Tropical Medicine
- Study Director: Moctar Ouedraogo, MsD, Centre MURAZ / AfricSanté, Burkina Faso
Publications and helpful links
General Publications
- Kasteng F, Murray J, Cousens S, Sarrassat S, Steel J, Meda N, Ouedraogo M, Head R, Borghi J. Cost-effectiveness and economies of scale of a mass radio campaign to promote household life-saving practices in Burkina Faso. BMJ Glob Health. 2018 Jul 16;3(4):e000809. doi: 10.1136/bmjgh-2018-000809. eCollection 2018.
- Sarrassat S, Meda N, Badolo H, Ouedraogo M, Some H, Bambara R, Murray J, Remes P, Lavoie M, Cousens S, Head R. Effect of a mass radio campaign on family behaviours and child survival in Burkina Faso: a repeated cross-sectional, cluster-randomised trial. Lancet Glob Health. 2018 Mar;6(3):e330-e341. doi: 10.1016/S2214-109X(18)30004-4.
- Head R, Murray J, Sarrassat S, Snell W, Meda N, Ouedraogo M, Deboise L, Cousens S. Can mass media interventions reduce child mortality? Lancet. 2015 Jul 4;386(9988):97-100. doi: 10.1016/S0140-6736(14)61649-4. Epub 2015 Feb 13.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-9-56
- 6028 (Other Identifier: UK: Research ethics committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States